期刊文献+

三阴性乳腺癌和HER-2过表达乳腺癌的临床病理特征比较 被引量:7

Clinical pathological features of triple-negative breast cancer and HER-2 overexpression breast cancer.
暂未订购
导出
摘要 目的探讨三阴性乳腺癌和HER-2过表达乳腺癌的临床病理特征。方法选取210例雌、孕激素受体均为阴性的乳腺癌患者为研究对象,根据HER-2检测结果将其分为两组,三阴性乳腺癌组(Estrogen Receptor ER、Progesterone Receptor PR和HER-2表达阴性)85例,HER-2过表达乳腺癌组(ER、PR阴性和HER-2表达阳性)125例,比较两组发病部位、病理类型、肿瘤直径大小、淋巴结转移、组织学分级、TNM分期、p53表达及Ki-67表达情况。结果两组在发病部位上差异无统计学意义(P=0.4317),均好发于外上象限部位,分别占58.82%和46.4%;两组在病理类型、肿瘤直径大小、TNM分期、p53表达上差异无统计学意义(P=0.6146、P=-0.2744、P=0.5909、P=0.6002),其中浸润性导管癌、直径为2-5cm、II期所占比例均最高;三阴性乳腺癌组淋巴结转移以阳性为主,占56.47%,HER-2过表达乳腺癌组以阴性为主,占67.2%,差异有统计学意义(P=.0007);两组在组织学分级上,差异有统计学差异(P=0.0278),其中组织学2级所占比例最高;三阴性乳腺癌组在Ki-67表达上与HER-2过表达组相比,有差异有统计学差异(P=0.0041)。结论三阴性乳腺癌和HER-2过表达乳腺癌的病理类型均好发在外上象限,以浸润性导管癌为主,就诊时均是II期病人为主。三阴性乳腺癌较HER-2过表达乳腺癌的侵袭性更强,细胞增殖更活跃,组织学分级更高,更易发生淋巴结转移,因此预后更差。 Objective To investigate the clinical pathological features of triple-negative breast cancer and HER-2 overexpression breast cancer. Methods A total of 210 patients with breast cancer of negative expression of estrogen and progesterone receptorses were selected as the research objects, which were divided into two groups according to the results of HER-2 detection: triple-negative breast cancer group (with negative expression of ER, PR and HER-2, n=85), HER-2 overexpression breast cancer group (with negative expression of ER, PR and positive expression of HER-2, n=125). The lesion site, pathological type, tumor size, lymph node metastasis, histological grade, TMN stage, P53 expression and Ki-67 expression of two groups were analyzed. Results There was no significant difference in lesion site between triple-negative breast cancer group and HER-2 overexpression breast cancer group (P=0.4317), and the upper outer quadrant area occupied the highest ratio, about 58.82% and 46.4%. There was no sig- nificant difference in pathological types, tumor size, TMN staging, and P53 expression between triple-negative breast cancer group and HER-2 overexpression breast cancer group (P=0.6146, P=-0.2744, P=0.5909, P=-0.6002), and the in- vasive ductal carcinoma, the tumor size (2-5 cm), and stage II occupied the highest ratio. Lymph node metastasis with positive in triple-negative breast cancer group accounted for 56.47%, and lymph node metastasis with negative in HER-2 overexpression breast cancer group accounted for 67.2%. The differences was statically significant (χ2=11.609, P=0.0007). The differences was statically significant in histological grade (P=-0.0278), and histological grade II occupied the highest ratio. The differences was statically significant in Ki-67 expression between triple-negative breast cancer group and HER-2 overexpression breast cancer group (P=-0.0041). Conclusion Triple-negative breast cancer and HER-2 overexpression breast cancer often occur in the upper outer quadrant area, and are mainly in invasive ductal carcinoma, and stage II. Triple-negative breast cancer is stronger in invasion, higher in histological grade, more apt to lymph node metastasis, and has a poorer prognosis than HER-2 overexpression in breast cancer.
出处 《海南医学》 CAS 2014年第6期906-909,共4页 Hainan Medical Journal
基金 河北省科技厅指导性计划(编号:08276101D-70) 张家口市科技局指导性计划(编号:1321090D)
关键词 三阴性乳腺癌 HER-2过表达乳腺癌 病理特征 Triple-negative breast cancer HER-2 overexpression breast cancer Clinical pathological features
  • 相关文献

参考文献13

二级参考文献108

  • 1曲建军,石毅然.MUC1与HER2基因在乳腺癌中的研究进展[J].中国肿瘤临床,2005,32(18):1073-1075. 被引量:5
  • 2赵卫红,徐兵河,张频,李青,赵龙妹,孙燕.乳腺癌合并脉管瘤栓的临床病理特点及预后因素分析[J].中华肿瘤杂志,2007,29(2):137-140. 被引量:14
  • 3Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 4Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recoannendations. J Natl Compr Canc Netw, 2006, 4 Suppl 3 :S1-22.
  • 5Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007, 8:235-244.
  • 6Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 7Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 2002, 77:148-154.
  • 8Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). Proc Am Soc Clin Oncol, 2006, 24 :abstr 508.
  • 9Herr A, Gluz O, Ting E, et al. Biological characteristics in triple negative high risk breast cancer and their clinical implications. Proc Am Soc Clin Oncol, 2006, 24 : abstr 20032.
  • 10Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19:264-271.

共引文献115

同被引文献41

  • 1陈曦,吴晶晶,张妍,欧阳学农,李捷.三阴性乳腺癌临床病理特征及与药物敏感度蛋白的相关性[J].肿瘤防治研究,2014,41(5):439-442. 被引量:15
  • 2E. Burandt,G. Jens,F. Holst,F. J?nicke,V. Müller,A. Quaas,M. Choschzick,W. Wilczak,L. Terracciano,R. Simon,G. Sauter,A. Lebeau.??Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer(J)Breast Cancer Research and Treatment . 2013 (3)
  • 3Sikov WM,Berry DA,Perou CM,et al.Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in StageⅡtoⅢTriple-Negative Breast Cancer:CALGB 40603 (Allianc. Journal of Clinical Oncology . 2015
  • 4Kyungji Lee,Ahwon Lee,Byung Song,Chang Kang.Expression of AIB1 protein as a prognostic factor in breast cancer. World Journal of Surgical Oncology . 2011
  • 5R. Schiff,C.K. Osborne,V. Bardou,T.A. Hopp,G.C. Chamness,S.G. Hilsenbeck,S.A.W. Fuqua,J. Wong,D.C. Allred,G.M. Clark.Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. Journal of the National Cancer Institute . 2003
  • 6Saegusa M,Okayasu I.Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Japanese Journal of Cancer Research . 2000
  • 7H. Iwase,Y. Omoto,T. Toyama,H. Yamashita,Y. Hara,H. Sugiura,Z. Zhang.??Clinical Significance of AIB1 Expression in Human Breast Cancer(J)Breast Cancer Research and Treatment . 2003 (3)
  • 8Dan Xie,Jonathan S.T. Sham,Wei-Fen Zeng,Han-Liang Lin,Jiong Bi,Li-Hong Che,Liang Hu,Yi-Xin Zeng,Xin-Yuan Guan.??Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma(J)Human Pathology . 2005 (7)
  • 9Nancy U. Lin,Ann Vanderplas,Melissa E. Hughes,Richard L. Theriault,Stephen B. Edge,Yu‐Ning Wong,Douglas W. Blayney,Joyce C. Niland,Eric P. Winer,Jane C. Weeks.??Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network(J)Cancer . 2012 (22)
  • 10杨德宏,刘红,赵晶.三阴型乳腺癌临床病理特征及预后分析[J].中国肿瘤临床,2008,35(9):501-504. 被引量:40

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部